A California Dermatology Roll-Up: Verified Market Research and an Acquisition Strategy

Situation

A physician-owned dermatology platform with an existing multi-state footprint set out to expand across California — the kind of ambition that reads simply on a whiteboard and gets expensive fast in practice. Healthcare-services consolidation is a crowded, private-equity-driven game: well-capitalized platforms are actively rolling up solo and small-group practices, valuations move quickly, and a buyer without a disciplined screen ends up overpaying for the wrong practice in the wrong market. Expanding “into California” isn’t a strategy; it’s a geography.

What made the timing interesting was a genuine window. California’s regulatory environment — including a $25M revenue/asset threshold for state Material-Change review — creates real friction for large PE buyers while leaving physician-led, sub-$25M acquisitions comparatively unobstructed. But windows close. What the platform needed before committing capital was the unglamorous, decisive work: which markets, which targets, at what multiple, against which competitors — verified, not assumed.

The engagement

CMA delivered a verified market-research and acquisition-strategy engagement — Milestone 1 of a disciplined expansion — with every figure tied to a source and every target checked.

Market context and a TAM/SAM/SOM built to matter

The work opened with the market: the U.S. dermatology services industry is roughly a $10.0 billion market growing at about 2.8% a year, with the cash-pay aesthetic segment now ~38.6% of it — the most profitable, least reimbursement-exposed part of the business. Then it narrowed fast, the way sizing should: a $1.16B TAM across the nine-county Bay Area, a ~$1.04B SAM in the primary one-hour catchment, and a realistic ~$40M five-year SOM for a four-to-six-location platform (grounded in a per-location patient benchmark, not a percentage of a big number). That funnel is what keeps an expansion honest about the prize.

Screening, competitor intelligence, and verified targets

Because the market is being actively consolidated, the strategy accounted for the other buyers — the PE-backed groups now operating 120+ California locations combined — and set a disciplined target profile: solo and small-group practices (one to four physicians), sub-$1M EBITDA, a medical-plus-cosmetic mix, and a PPO-weighted payer profile, all of which keep deals below platform-pricing dynamics and the state’s $25M review threshold. Against that profile, the engagement produced 11 verified acquisition targets — verified being the operative word: each was checked against the practice’s own records, the state medical board, the NPI registry, and platform announcements, distilled down from a longer initial list to the ones that survived scrutiny.

A four-tier roadmap and a formula-driven model

Finally, the research was carried all the way to a sequenced plan and a working model. A four-tier roadmap ordered the moves by risk and timing — Tier 1 anchor acquisitions in the primary Bay Area market ($1.5–4.5M, 0–6 months), Tier 2 de-novo greenfield builds ($1.0–2.6M, 6–12 months), Tier 3 lifestyle-market acquisitions on the coast ($2.0–5.0M, 9–18 months), and a Tier 4 watch pipeline — underpinned by 3–5x EBITDA valuation math and a ~$4.3M balanced-scenario Year-1 capital deployment (including working-capital reserves). All of it sits in a fully formula-driven Excel model where every revenue, cost, EBITDA, and exit-valuation figure flexes from a transparent assumptions tab.

Why the structure mattered

The framing decision was to screen, verify, and value before sourcing. Most roll-ups fail on the first few deals — overpaying in a market that looked good from a distance, against competitors they didn’t map, on targets they didn’t verify. Doing the TAM/SAM/SOM, the competitor intelligence, the source-checked target list, and the valuation model first is what turned “let’s expand in California” into a disciplined, sequenced pipeline with the numbers attached.

Impact

The platform left Milestone 1 with a verified market read, 11 screened targets, a four-tier acquisition roadmap, and a formula-driven valuation model — plus a clear view of the regulatory window it can move through while larger buyers can’t. In PE-driven consolidation, discipline on the first acquisition sets the economics of every one that follows.